Switching to Fluoxetine for Bulimia Nervosa in a Patient Stable on Sertraline
Fluoxetine is the only medication actually approved for bulimia nervosa. This patient is already stable on sertraline for a pre-existing depression. Whether the approval reflects real superiority or just which drug happened to get the pivotal trial is the question the team has to answer before touching a regimen that's currently working.
A.T., a 29-year-old woman, has worked night shifts on a pediatric unit for four years, and says the schedule — sleeping through most days, eating alone at odd hours, no one around to notice a pattern — is probably part of why it took her this long to tell anyone what had actually been happening most nights after her shift. She has been treated for major depressive disorder since her mid-twenties, stable for the past two years on sertraline 150mg, well-controlled enough that she and her psychiatrist had been discussing a slow taper before any of this came up. Three months ago, at a routine follow-up, she disclosed binge-purge episodes that had actually started well before that — roughly eight months of eating large amounts of food in a short window, almost always alone, followed by self-induced vomiting, occurring most nights she worked.
Since disclosure and the start of concurrent CBT for bulimia, the frequency has already come down on its own — from nearly nightly to about twice a week — which the team reads as a genuinely encouraging early response to therapy rather than something the medication conversation should overshadow. The actual question in front of the team is narrower than "does she need an SSRI" — she's already on one, and it's working for her depression. It's whether to switch her specifically to fluoxetine, the only medication carrying an FDA indication for bulimia nervosa, or to keep her on sertraline and simply optimize the dose she's already stable on. The approval itself traces to a single pivotal trial — the Fluoxetine Bulimia Nervosa Collaborative Study Group, 1992 — which found a genuine dose-response relationship: 60mg produced significantly greater reduction in binge and purge frequency than 20mg or placebo. What that trial does not settle is whether fluoxetine is pharmacologically special for bulimia, or whether it simply happened to be the molecule one company took through the specific trial the FDA required, while other SSRIs with smaller, less commercially pursued positive data — fluvoxamine among them — never got the same regulatory attention. Switching her now means a cross-taper, a period of dual serotonergic exposure or a washout gap, and real risk to two years of hard-won depression stability, for a question that may come down to trial history more than pharmacology.
Medication review, three months into the bulimia diagnosis
I think we should switch her to fluoxetine. It's the only SSRI actually studied and approved for bulimia nervosa specifically — binge and purge frequency as the trial's own endpoint, not depression. Sertraline has never been tested that way in this population. If we're treating a new diagnosis, I'd rather use the drug that was built and proven for it.
I want to separate what the approval actually tells us from what it sounds like it tells us. The Fluoxetine Bulimia Nervosa Collaborative Study Group's 1992 trial found a real dose-response relationship — 60mg beat 20mg and placebo on binge/purge frequency — and that's what earned the FDA indication. But that trial tells us fluoxetine works at that dose; it doesn't tell us sertraline doesn't, because sertraline was never put through the same test. Smaller positive trials exist for other SSRIs in bulimia, fluvoxamine among them, that simply never got pursued to a full FDA indication — the commercial incentive to run that specific trial existed for one company, not the whole class. A.T. has been stable for two years on sertraline. Cross-tapering her now means either a washout gap or a period of dual serotonergic exposure, real risk to a depression that's taken two years to get this controlled, for a switch whose justification may be trial history more than pharmacology.
I'd also point out the binge/purge frequency is already dropping on CBT alone — we're not choosing between "medicated" and "unmedicated," we're choosing between two already-active SSRIs.
You're both pointing at real pieces of the same trial and landing in different places — I think there's a third option that uses the trial's actual finding without touching a medication that's working. The cleanest, most replicated result from the 1992 study isn't "fluoxetine specifically," it's the dose-response curve: 60mg meaningfully outperformed 20mg. Sertraline's own effective range for depression tops out well below what's typically pushed for bulimia-type serotonergic effects. Rather than switching molecules, I'd uptitrate her sertraline toward the higher end of its own approved range, watch binge/purge frequency alongside continued CBT, and hold fluoxetine in reserve if that doesn't move further. It's the most direct way to act on what the evidence actually showed without gambling with two years of depression stability.
Agreed: uptitrate sertraline to 200mg rather than switch to fluoxetine, continue weekly CBT, and monitor binge/purge frequency and depression symptoms together over the next eight weeks. Fluoxetine remains an explicit, named fallback if the higher dose doesn't produce further improvement.
Not agreed: how long to wait before considering the switch to fluoxetine if progress stalls rather than continuing to climb. The Attending Psychiatrist wanted a defined trial window — eight weeks at the higher sertraline dose, then switch if frequency hasn't dropped further — worried that an open-ended "watch and see" could let the bulimia-specific indication go untried indefinitely. The Psychiatric Pharmacist preferred leaving the exact timeline flexible, tied to A.T.'s actual trajectory rather than a fixed calendar date, since her depression stability is the harder-won and more fragile thing to protect. Both agreed to reassess formally at the eight-week mark regardless.
Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →